HOME
ABOUT US
DAIICHI SANKYO
NEWS
CAREER
OPPORTUNITIES
CONTRACT MANUFACTURING
SERVICES
CONTACT US
American Regent
Animal Health
Osteohealth

News

  U.S. Reining Team to wear Adequan® Brand at 2014 World Equestrian
6/20/2014
  Shirley, NY (May 23, 2014) - Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturers of Adequan® i.m. (polysulfated glycosaminoglycan), Adequan® I.A. (polysulfated glycosaminoglycan), and Adequan® Canine (polysulfated glycosaminoglycan) provides the following supply update
5/23/2014
  American Regent’s Injectafer® (Ferric Carboxymaltose Injection) Assigned Q Code by Centers for Medicare and Medicaid Services
5/7/2014
  Luitpold Animal Health - Adequan Press Release
4/1/2014
  Sunshine Act Statement
10/22/2013
  Injectafer® (ferric carboxymaltose injection) receives US FDA approval for the treatment of Iron Deficiency Anemia
7/25/2013
  American Regent announces new PDUFA action date for Injectafer® (ferric carboxymaltose injection) NDA for the treatment of iron deficiency anemia
4/8/2013
  Epinephrine Injection, USP Important Drug Administration Information
2/5/2013
  Methylergonovine Heathcare Professional Letter
12/20/2012
  American Regent Anounces an FDA Pediatric Indication Exclusivity for Venofer (Iron Sucrose Injection, USP)
10/19/2012
  American Regent announces a new FDA-Approved Pediatric Indication for Venofer® (Iron Sucrose Injection, USP)
9/26/2012
  Luitpold Pharmaceuticals, Inc. Receives Complete Response Letter for Injectafer® from the U.S. Food and Drug Administration
7/26/2012
  National Registry Study Evaluating Utility of SPRIX® (ketorolac tromethamine) Nasal Spray, a Non-Narcotic Alternative for Pain Management after Emergency Department Care, Begins
6/25/2012
  American Regent Initiates Nationwide Voluntary Recall of Cyanocobalamin Injection, USP, 1000 mcg/mL, 1 mL Vial, Lot #s 1662, 1679, 1683 Due to Cracks in the Vials
4/2/2012
  FDA Assigns PDUFA Date for Injectafer® (ferric carboxymaltose injection) NDA
12/15/2011
123

DAIICHI SANKYO NAMES NEW PRESIDENT OF US SUBSIDIARY LUITPOLD PHARMACEUTICALS, INC.

June 29, 2016 – Effective today, Ken Keller has been newly appointed as President and CEO of Luitpold Pharmaceuticals, in addition to his current position as President, Daiichi Sankyo Administrative and Commercial, Daiichi Sankyo, Inc.

With more than 25 years of experience in the pharmaceutical industry in commercial leadership and joint venture leadership, Mr. Keller will now oversee both the Daiichi Sankyo, Inc. Commercial organization and Luitpold Pharmaceuticals, Inc.

Mr. Keller joined Daiichi Sankyo, Inc. in 2014 and has also served on the Luitpold Board of Directors since 2015. He has successfully led the Daiichi Sankyo, Inc. US commercial organization as it begins its transformation to a specialty focused company.

“While Luitpold and Daiichi Sankyo US businesses serve different customers and markets, they each bring to the table important strengths and focus that are essential to the continued success and growth of the Daiichi Sankyo Group,” said Ken Keller. “I look forward to working with the Luitpold team and driving even further success in the future.”

Luitpold Pharmaceuticals, Inc. is a Daiichi Sankyo Group Company headquartered in Shirley, NY, and manufactures more than 80 pharmaceutical products.